AMENDING AGREEMENT
THIS AGREEMENT made as of the 30th day of April, 2026.
AMONG:
SHAREHOLDERS OF CLINIQUANTUM LTD.
as set out in Section 3.03 of the Disclosure Schedules (as defined in the SPA (as defined below))
(hereinafter referred to as the “Selling Shareholders”)
OF THE FIRST PART
-and-
CLINIQUANTUM LTD.
a corporation incorporated under the laws of the State of Israel
(hereinafter referred to as the “Company”)
OF THE SECOND PART
-and-
NEUROTHERA LABS INC.
a corporation incorporated pursuant to the laws of the Province of British Columbia and having its registered head office located at 2264 E 11th Ave., Vancouver, British Columbia V5N 1Z6
(hereinafter referred to as the “Purchaser”)
OF THE THIRD PART
…